Who is the President of Singapore, on whom the Union Finance Minister is to call during her visit?

The correct answer is Singapore. The city state is India’s largest source of foreign direct investment, with cumulative inflows of roughly USD 194.68 billion between April 2000 and March 2026, and its institutional investors, among them GIC and Temasek, hold significant positions across the Indian economy. This standing is one reason the Union Finance Minister’s engagements there centre on capital markets, taxation and digital financial connectivity. Option A, Mauritius, was for years the leading route for investment into India and is still a major one, which is exactly why it is the most tempting wrong answer here. Option C, the United States, and option D, Japan, are both large investors and important economic partners, but neither tops the table of cumulative inflows. For objective papers, hold Singapore at the first place and Mauritius immediately behind it as the pair most often swapped in questions.

The correct answer is USD 194.68 billion. That is the cumulative figure for foreign direct investment flowing from Singapore into India over the period from April 2000 to March 2026, and it is the number behind the description of Singapore as India’s single largest source of such investment. Option A, at 94.68 billion, and option B, at 144.68 billion, both fall well short of the recorded total and would place Singapore lower in the table of investing countries than it actually stands. Option D, at 234.68 billion, overstates the inflow. Along with the figure, note the window it covers, which begins in April 2000, because the same number is meaningless without the period; and remember the two Singaporean institutional investors named with it, GIC and Temasek, along with the National Investment and Infrastructure Fund and GIFT City as the Indian platforms held out for further Singaporean capital.

The correct answer is GIC and Temasek. GIC, the Government of Singapore Investment Corporation, and Temasek Holdings are the two Singaporean institutional investors named as having significant investments spread across the Indian economy, and the Union Finance Minister is to hold separate meetings with the chief executives of both. Option B pairs Temasek with Mubadala, which is an investment company of the United Arab Emirates and not Singaporean. Option C pairs GIC with Khazanah Nasional, the sovereign fund of Malaysia, so the pair again mixes countries. Option D names the National Investment and Infrastructure Fund and GIFT City, which belong on the other side of the transaction: they are the Indian platforms offered as routes through which Singaporean capital can participate more fully, including through investment vehicles and funds, and not investors from Singapore.

The correct answer is 42. In February 2019, on the direction of the Government, the pricing authority capped trade margins on 42 selected non-scheduled anti-cancer drugs, using Paragraph 19 of the Drugs (Prices Control) Order, 2013. That decision brought retail prices down by up to 91 per cent across 526 brands and was reported to save patients Rs 984 crore a year, which is why it is cited as the precedent for the wider cap approved now. Options A, C and D are near misses designed to test whether the figure has been memorised precisely rather than roughly; none of them was the number of drugs covered. A useful way to hold the 2019 decision in mind is the chain of four numbers that go with it: 42 drugs, 526 brands, prices lower by up to 91 per cent and a yearly saving of Rs 984 crore.

The correct answer is the National Pharmaceutical Pricing Authority. Two bodies have distinct roles here, and the question turns on telling them apart. An expert committee under the Directorate General of Health Services will finalise the list of medicines that the cap should cover; once that list is ready, the National Pharmaceutical Pricing Authority will take the decision and issue the notification giving the cap legal effect. Option D, the Directorate General of Health Services, therefore comes earlier in the sequence and does not notify prices. Option A, NITI Aayog, is the Government policy think tank and has no role in fixing medicine prices. Option C, the Central Drugs Standard Control Organisation, is the national drug regulator concerned with approvals, quality and safety of medicines rather than with what they cost. The pricing authority is also the body that capped trade margins on selected anti-cancer drugs in February 2019.